Skip to main content

Table 4 Delta changes in the explorative measurements from baseline to follow up time point

From: A randomized controlled trial on a multicomponent intervention for overweight school-aged children – Copenhagen, Denmark

  n Control ∆adj n Intervention ∆adj n Intervention effect ∆adj P value
Glycemic control        
 HbA1c (mmol/mol) 12 -0.3 (-0.8; 0.1) 14 -0.5 (-0.9; -0.1) 26 -0.2 (-0.8; 0.5) 0.6
Oral glucose tolerance test        
  Fasting glucose (mmol/L) 14 0.1 (-0.1;0.3) 14 0.1 (-0.1; 0.2) 28 0.0 (-0.3; 0.3) 0.4
  Fasting insulin (mmol/L) 13 -4.7 (-17.6; 8.2) 12 -13.4 (-26.7; -0.1) 25 -8.7 (-27.4; 10.0) 0.3
  120 min (2 h) glucose (mmol/L) 10 0.6 (-0.1; 1.3) 13 0.1 (-0.5; 0.7) 23 -0.5 (-1.4; 0.4) 0.3
  Matsuda Index 9 -3.4 (-10.2; 3.5) 12 7.4 (1.9; 13.0) 21 10.8 (1.4; 20.2) P <0.03
  HOMA-IR 13 0.1 (-0.5; 0.3) 12 -0.4 (-0.8; 0.1) 25 -0.3 (-0.9; 0.3) 0.3
 Mean 48 h BG (mmol/L) by CGMS 7 0.1 (-0.6; 0.9) 9 -0.3 (-1.0; 0.4) 16 -0.4 (-1.5; 0.7) 0.4
Biochemistry        
 Alanintransaminase (U/l) 12 -7.9 (-12.6; -3.3) 14 -9.1 (-13.3; -4.8) 26 -1.1 (-7.4; 5.2) 0.7
 Aspartattransaminase (U/l) 12 -2.0 (-5.1; 1.1) 14 -2.9 (-5.8; 0.0) 26 -0.9 (-5.1; 3.3) 0.7
 Thyrotropin (x10-3int.enh./l) 14 0.1 (-0.4; 0.6) 14 0.3 (-0.1; 0.8) 28 0.2 (-0.5; 0.9) 0.5
 Triiodthyronin (nmol/l) 14 -0.2 (-0.3; 0.0) 14 -0.2 (-0.4; -0.1) 28 -0.1 (-0.3; 0.1) 0.5
 Thyroxin (nmol/l) 14 0.8 (-3.9; 5.5) 14 -0.6 (-5.3; 4.1) 28 -1.4 (-8.0; 5.3) 0.7
 Total cholesterol (mmol/L) 14 -0.3 (-0.5; 0.0) 14 -0.5 (-0.8; -0.3) 28 -0.3 (-0.6; 0.0) 0.07
 LDL (mmol/L) 14 -0.1 (-0.3; 0.1) 14 -0.4 (-0.6; -0.2) 28 -0.3 (-0.6; 0.0) 0.06
 HDL (mmol/L) 14 0.1 (0.0; 0.1) 14 0.0 (-0.1; 0.1) 28 -0.1 (-0.2; 0.1) 0.4
 Triglycerides (mmol/L) 14 -0.1 (-0.2; 0.0) 14 -0.3 (-0.4; -0.1) 28 -0.2 (-0.3; 0.0) 0.1
 Estradiol (pmol/L) 13 -11.8 (-22.4; -1.2) 13 -14.8 (-25.5; -4.1) 26 -3.0 (-18.6; 12.5) 0.7
 Testosterone (nmol/L) 12 0.0 (0.0; 0.1) 13 0.0 (0.0; 0.1) 25 0.00 (-0.1; 0.1) 1
 Sex hormone-binding globulin (nmol/L) 13 4.2 (-2.4; 10.8) 13 17.0 (10.5; 23.5) 26 12.9 (3.5; 22.3) P <0.01
 Follicle-stimulating hormone (IU/L) 13 0.1 (-0.2; 0.3) 13 0.0 (-0.3; 0.2) 26 -0.1 (-0.4; 0.3) 0.7
 Luteinizing hormone (IU/L) 13 0.0 (-0.1; 0.3) 13 0.0 (-0.2; 0.2) 26 -0.1 (-0.3; 0.2) 0.5
 IGFBP-3 (ng/mL) 13 -73.2 (-233.5; 87.0) 13 -124.5 (-291.0; 42.0) 26 -51.3 (-293.0; 190.4) 0.7
 Insulin-like growth factor 1 (ng/mL) 13 49.8 (15.1; 84.5) 13 4.4 (-30.2; 39.1) 26 -45.4 (-94.5; 3.8) 0.07
 Adiponectin (ng/mL) 12 -1,693 (-3,143; -242) 13 595 (-801; 1,990) 25 2,287 (254; 4,320) P <0.05
 Leptin (pg/mL) 11 -7,803 (-15,402; -205) 14 -14,374 (-21,069; -7,679) 25 -6,570 (-16,944; 3,803) 0.2
 Resistin (ng/mL) 12 -0.4 (-0.9; 0.1) 14 -0.6 (-1.0; -0.1) 26 -0.2 (-0.8; 0.5) 0.6
 Visfatin (ng/mL) 10 0.0 (-0.3; 0.2) 11 0.2 (-0.1; 0.4) 21 0.2 (-0.2; 0.5) 0.3
  1. P values are representing the intervention effects (the difference in change between the groups) adjusted for the respective baseline values (95% confidence intervals).
  2. P values assessed by ANCOVA.
  3. Mean 48 h BG (mmol/L) by CGMS, mean blood glucose measured in 48 h by continuous glucose monitoring system.
  4. HbA1c, glycosylated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; IGFBP-3, Insulin-like growth factor-binding protein 3.